临床试验登记· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · ClinicalTrials.gov·· 2 天前评分35
Trastuzumab Rezetecan序贯Pyrotinib、Fulvestrant和Dalpiciclib治疗HR阳性、HER2阳性晚期乳腺癌
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
导读
中山大学孙逸仙纪念医院登记NCT07892274三期试验，拟纳入226例HR阳性、HER2阳性晚期乳腺癌患者。试验比较trastuzumab rezetecan诱导后换用pyrotinib、fulvestrant、dalpiciclib三药与继续前者的无进展生存期。试验尚未招募，计划2026-11-01启动。
来源：临床试验登记 · clinicaltrials.gov